Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-04

Study Completion Date

2022-04-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The scientific rationale for this study is the evolving understanding that iron-induced tissue damage is not only a process of progressive bulking of organs through high-volumes iron deposition, but also a reactive iron species related "toxic" damage.

Iron mediated damage can occur prior reaching high iron storage thresholds derived from thalassemia major setting, free toxic iron species being already present when transferrin saturation \>60-70% (25); therefore a timely early adoption of iron chelation may be of benefit before overt iron overload is seen.

Our hypothesis is that early and low dose DFX-FCT is better tolerated and is able to prevent iron accumulation and consequently tissue iron related damage, by consistently suppressing iron reactive oxygen species (NTBI and LPI).

If this hypothesis is confirmed this approach could contribute to an improvement of clinical practice of patients managements. Additionally this approach might also be a contribute in preventing future iron overloaded related complication, in this already frail and co-treated patient population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study

NCT01033747

Liver Iron Overload

COMPLETED PHASE2/PHASE3

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

NCT01459718

Transfusion-dependent β-thalassemia Patients Cardiac Iron Overload

TERMINATED PHASE2

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00117507

Myelodysplastic Syndromes Iron Overload

COMPLETED PHASE4

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00110266

Myelodysplastic Syndrome Iron Overload

COMPLETED PHASE2

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

NCT00061763

Beta-thalassemia Myelodysplastic Syndromes Fanconi Syndrome +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelodysplastic Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is an open-label, single arm, phase II, study designed to look whether early intervention with low dose DFX improves clinical outcome of patients with MDS.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Deferasirox

patients will be assigned to a fixed dose of 3.5 mg/kg/day of DFX FCT.

Group Type EXPERIMENTAL

Deferasirox

Intervention Type DRUG

Fixed dose of 3.5 mg/kg/day of DFX FCT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deferasirox

Fixed dose of 3.5 mg/kg/day of DFX FCT

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Exjade

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis: Adult Myelodysplastic Syndrome (≥18 years).
* Revised IPSS: very low. low - intermediate
* Having received 5-20 packed red blood cell units
* Serum ferritin ≥300 ng/ml
* Transferrin saturation ≥ 60%
* Chelation naïve
* Capability to provide informed consent

Exclusion Criteria

* Patients aged \<18 years old
* Higher risk (revised IPSS) MDS (Intermediate 2, high)
* Cumulative transfusion story of \> 20 packed red cell units
* Creatinine Clearance (CrCL): \<60 ml/min. Patients with CrCl of 40-60ml/min will be included only individually if no other renal risk factors are present.
* Serum creatinine \>2 x ULN at screening. If borderline serum creatinine will be measured within 7-10 days and the mean value will be used for eligibility criteria.
* Significant proteinuria as indicated by a urinary protein/creatinine ratio \> 0.5 mg/mg in a non-first void urine sample (or alternatively in two of three samples obtained for screening).
* ECOG performance status \>2.
* Left ventricular ejection fraction \< 50% by echocardiography
* A history of repeated hospitalization for congestive heart failure.
* Systemic diseases that would prevent study treatment (e.g. uncontrolled hypertension, cardiovascular, renal, hepatic, metabolic, etc.)
* Clinical or laboratory evidence of chronic Hepatitis B or Hepatitis C (definition of chronic hepatitis follows EASL 2017 criteria).
* History of HIV positive test result (ELISA or Western blot).
* Treatment with systemic investigational drug within 4 weeks or topical investigational drug within 7 days of study start.
* ALT or AST over 3 times superior to ULN at screening.
* ANC \< 500/ microL
* Platelets transfusion dependency
* Total bilirubin over 1.5 times superior to ULN at screening (patients with Gilbert syndrome are allowed to enter the study)
* Diagnosis of Child score C liver cirrhosis.
* Patients participating in another clinical trial other than an observational registry study.
* Patients with a history of another malignancy within the past 3 years, with the exception of basal skin carcinoma or cervical carcinoma in situ or completely resected colonic polyps carcinoma in situ.
* History of non-compliance to medical regimens, or patients who are considered potentially unreliable and/or not cooperative.
* Presence of a surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug.
* Pregnant, intending-to-become pregnant, or breast-feeding patients.
* Women of potential maternity age who do not agree to practice effective contraceptive methods fo the entire study duration.
* History of drug or alcohol abuse within the 12 months prior to enrollment.
* Hypersensitivity to the active substance or to any of the excipients.
* Inability to provide a valid informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No